Cil, O., Chu, T., Lee, S., Haggie, P
A large percentage of patients eventually discontinue injectable obesity medications because of cost, tolerability, supply, injection fatigue, or access barriers
Evidence indicates that dysfunctions in both inherent and adaptive immune pathways significantly contribute to the aberrant intestinal inflammation observed in IBD patients [215]
Your Alan Health provider can help you decide
Let's be realistic about actual legal consequences
Off-label use is consistently denied by payers unless they have a published policy with expanded diagnosis coverage or unique frequency limitations